Medpace shares traded lower Friday as the market continued to digest the company’s 2026 outlook and what it signals about demand and project durability. The key pressure point has been the February 10, 2026 guidance package, which pointed to materially slower growth versus 2025—an outcome that has kept sentiment fragile and made the stock prone to down days even without a fresh headline. (investing.com)

Medpace guided 2026 revenue to $2.755B–$2.855B (about 8.9%–12.8% growth) after delivering 20% growth in 2025, with 2026 EPS implied at $16.68–$17.50 (about 9.2%–14.5% growth) versus 21% EPS growth in 2025. That deceleration narrative has remained the central debate for the stock and continues to weigh on incremental buying interest. (investing.com)

Alongside guidance, management commentary referenced elevated cancellations in the metabolic therapeutic area, and investors have focused on how quickly bookings/backlog can normalize. With a revenue base still heavily tied to small biopharma customers, the market is also sensitive to any sign that biotech financing conditions could restrain trial starts and CRO outsourcing budgets. (investing.com)

Traders will be watching for (1) any incremental updates on cancellations and backlog conversion, (2) fresh analyst target changes following the March 6, 2026 Barclays rating change and other recent coverage, and (3) signs that small-biotech funding conditions are stabilizing enough to re-accelerate outsourcing demand. Any improvement in bookings metrics could quickly shift the tone given how much of the recent volatility has been tied to expectations for 2026 growth. (marketbeat.com)